

BioVersys

FY25 results

A step-change year for development activity

BioVersys's **FY25 results** underscore a transition into a catalyst-rich, late-stage development phase. Following FDA clearance, first patient dosing in the registrational Phase III trial for lead asset BV100 is set to commence in April 2026. The Phase IIb real-world evidence study will run in parallel, supported by the Wellcome Trust-funded ADVANCE-ID network, with both studies reading out in H227. Pipeline momentum extends to alpipectir (partnered with GSK), where a GSK-led Phase IIb/c pulmonary TB study initiated in March 2026, while a Phase IIb TB meningitis trial (BioVersys-led) is planned for Q226. Dual readouts by end-2027 are expected to shape the Phase III strategy. Earlier-stage assets BV500 (Shionogi collaboration) and BV200 continue to progress, adding pipeline depth. Reflecting BV100's advancement into Phase III, we increase its probability of success (PoS) to 60% (from 50%), driving a valuation uplift to CHF71.3/share (from CHF61.9).

Year end	Revenue (CHFm)	PBT (CHFm)	EPS (CHF)	DPS (CHF)	P/E (x)	Yield (%)
12/24	1.2	(18.7)	(5.62)	0.00	N/A	N/A
12/25	3.3	(21.8)	(3.89)	0.00	N/A	N/A
12/26e	4.6	(40.6)	(7.24)	0.00	N/A	N/A
12/27e	6.8	(35.3)	(6.29)	0.00	N/A	N/A

Note: PBT and diluted EPS are on a company reported basis.

BV100 set for Phase III

BV100 is approaching a key inflection point as it advances towards Phase III (RIV-TARGET) in VABP and HABP, supported by encouraging Phase II data. Following FDA clearance in March 2026, first patient dosing is expected in April. In parallel, the Phase IIb RIV-CARE study will generate real-world evidence in drug-resistant populations, strengthening BV100's clinical and commercial positioning. The next 18–24 months will be catalyst-rich, with interim data (H226), DSMB reviews (H226/H127) and top-line readouts (H227) expected to shape the approval pathway.

Mid-stage momentum builds for alpipectir

2026 should also see momentum building for second asset alpipectir across both partnered and internal programmes. Partner GSK has initiated a Phase IIb/c trial in pulmonary tuberculosis (TB, first patient dosed in March 2026), while BioVersys is preparing to commence a Phase IIb study in TB meningitis in Q226, targeting a high unmet need population. The dual-track strategy expands the asset's clinical and commercial potential, with readouts from both studies, expected by end-2027, key to defining the Phase III pathway and overall positioning.

Valuation: CHF416.2m or CHF71.3 per share


With the Phase III regulatory clearance and commencement for BV100, we raise the PoS for the programme to 60% (previously 50%), while keeping all other long-term assumptions unchanged. Reflecting this and the latest net cash (CHF60.8m at end-FY25), our valuation for BioVersys upgrades to CHF416.2m or CHF71.3/share (from CHF361.6m or CHF61.9/share). Based on management guidance (operating loss of CHF40–45m in FY26), 2027 debt maturities and our burn estimates, we see BioVersys funded into 2028, past key inflection points.

Healthcare

26 March 2026

Price	CHF27.80
Market cap	CHF165m
	CHF0.79/\$
Net cash at 31 December 2025	CHF60.8m
Shares in issue	5.8m
Free float	73.0%
Code	BIOV
Primary exchange	SWX
Secondary exchange	N/A

Share price performance



Business description

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on the development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria.

Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

BioVersys is a research client of Edison Investment Research Limited

Pipeline offers a range of potential upcoming catalysts

BioVersys is focused on the development of novel antibacterial treatments for serious, life-threatening, multi-drug resistant infections (Exhibit 1). As a reminder, the company's candidates originated from its proprietary discovery platforms, the ansamycin discovery and transcriptional regulator inhibitory compound (TRIC) platforms, adding scope to its value offering by providing a sustainable engine for generating novel candidates with differentiated mechanisms to overcome resistance. Encouragingly, clinical-stage candidates BV100 and alpipectir both have Qualified Infectious Disease Product designations, giving five additional years of market exclusivity and eligibility for priority review. Alpipectir also has Orphan Drug designation, offering tax credits for qualifying trials, user fee exemptions and up to seven years of exclusivity.

We provide an overview of the current ongoing activities for each of BioVersys's drug candidates below. For a more detailed discussion of the company's background and clinical data to date, we direct readers to our recently published initiation of coverage [note](#).

Exhibit 1: BioVersys drug development pipeline

Program	Indication	R&D/Preclinical	Phase 1	Phase 2	Phase 3	Expected Key Catalyst	Commercial Rights
BV100 FDA QIDP	Hospital infections <i>Acinetobacter baumannii</i> (VABP/HABP & BSI)  					FPFV: April 2026 FPFV: H1 2026	
							
Alpipectir FDA QIDP Orphan Drug FDA/EMA	Tuberculosis: • Multi-drug resistant • TB-Meningitis   	 				Phase 2b/c start: March 2026 Phase 2 start: H1/2026	 
BV200 Anti-virulence TRIC platform	Atopic dermatitis <i>Staphylococcus aureus</i> 					IND Filing: H1 2027	
BV500 Ansamycin platform	CF and COPD: Non-tuberculous mycobacteria infection CF AMR Syndicate 					License Option: 2027	 license option
BV Discovery	Targets undisclosed						

Source: BioVersys Annual Report 2025

BV100

Lead asset BV100 is a product of BioVersys's ansamycin discovery programme, and is an intravenous rifabutin formulation being developed for carbapenem-resistant *Acinetobacter baumannii* (CRAB) infections, one of the highest priority antibiotic-resistant pathogens. BV100 is currently involved in the registrational Phase III RIV-TARGET programme focused on ventilator-associated bacterial pneumonia (VABP, for which encouraging data have previously been generated in Phase IIb), alongside hospital-acquired bacterial pneumonia (HABP). The FDA provided [regulatory clearance](#) for RIV-TARGET in March 2026 (Exhibit 2).


RIV-TARGET is designed as a randomised, active-controlled, two-part parallel-group Phase III trial (expected n=300). Participants will be randomised 1:1 to receive either BV100 plus low-dose polymyxin B (primary last-resort therapy for CRAB infections) or a standard-of-care regimen of colistin plus high-dose ampicillin-sulbactam, with meropenem permitted as background therapy in cases of polymicrobial infection. The primary endpoint is 28-day all-cause mortality. The design broadly mirrors the prior Phase II study in VABP, where BV100 demonstrated a meaningful survival signal versus best available therapy (25%, vs 60% mortality). The trial includes an open-label, non-randomised cohort (Part B) evaluating BV100 plus low-dose polymyxin B in treatment-refractory patients, including those with CRAB infections resistant to polymyxins or where prior polymyxin-based therapy has failed. Approximately 25 participants are anticipated to be enrolled in this cohort. Management has communicated that the trial is on track to dose the first patient in RIV-TARGET in April 2026, representing a key upcoming milestone.

Alongside Phase III, BioVersys is also advancing the open-label Phase IIb RIV-CARE study, which will be conducted

with the ADVANCE ID network and supported by Wellcome funding. This study is expected to begin in Q226 and is intended to generate additional real-world evidence for BV100 in settings with very high drug resistance. We see this as strategically important, as it should help sharpen the future commercial positioning of BV100 and support discussions with potential partners and regulators. Separately, BioVersys initiated a China Phase I bridging study in [November 2025](#), which should allow Chinese sites to join the global Phase III programme from H226.

Looking ahead, the key milestones for 2026 will be the commencement of patient dosing in both RIV-TARGET and RIV-CARE, completion of the China Phase I study and an interim update from RIV-CARE by end-2026. Beyond this, company guidance points to top-line data from both RIV-TARGET and RIV-CARE by end-2027. Importantly, management has stated that the Phase III package has been shaped through regulatory interactions with the FDA, EMA and Chinese authorities, with the intention of supporting approval discussions across all three jurisdictions. Should these operations remain on track, and the efficacy signals seen in Phase II translate into Phase III, BV100 has the potential to become BioVersys's first commercial product and the central value driver for the company over the medium term.

Exhibit 2: Design of the registrational Phase III RIV-TARGET trial



1. Treatment failure, VAPB due to colistin-resistant *Acinetobacter* or patients with known intolerance to colistin.

Source: BioVersys corporate presentation Q1 2026

Alpibectir

Alpibectir originated from the TRIC platform, and is, to our knowledge, the most advanced small molecule drug candidate targeting bacterial transcriptional regulators for TB treatment. It is currently being developed in partnership with GSK, where development costs and any future net revenues are shared on a 50/50 basis. A dual strategy is being taken with alpibectir, whereby the candidate is being developed for two indications in parallel: drug-resistant pulmonary TB (led by GSK) and TB meningitis (led by BioVersys).

For GSK, the current priority for alpibectir is the ongoing Phase IIb/c trial, for which the first patient was dosed in [March 2026](#), evaluating AlpE (alpibectir in combination with the TB treatment potentiator ethionamide) in pulmonary TB. More specifically, the study has been designed to test AlpE in combination with three first-line TB drugs (rifampicin, pyrazinamide and ethambutol) in drug-susceptible TB patients for two months, followed by standard therapy alone (rifampicin and isoniazid) for an additional 18 weeks. Key outcome measures are based on efficacy, safety and pharmacokinetics. Top-line results are expected by end-2027. The trial is being conducted within the UNITE4TB consortium, a public-private partnership, and is taking place across six African countries. The programme builds on an earlier Phase IIa open-label, 14-day study ([ENABLE trial](#)) assessing AlpE alongside first-line TB therapy. Top-line data for ENABLE are anticipated in Q226.

For BioVersys, the focus for alpibectir is on TB meningitis, where the company is preparing for a Phase IIb trial. This is expected to be a multicentre, open-label, randomised, active-controlled study assessing the pharmacokinetics, safety and exploratory efficacy of AlpE in newly diagnosed TB meningitis patients. Patient recruitment is on track to commence in Q226, representing a key upcoming milestone for the programme. We expect trial conclusion during 2027.

We understand that BioVersys and GSK are aligned on the subsequent Phase III strategy focusing on a single pivotal trial in TB meningitis, rather than pulmonary TB. The significant unmet medical need and orphan indication status should enable use of the [Limited Population Pathway for Antibacterial and Antifungal Drugs](#), allowing approval based on relatively small study patient populations. Importantly, this focused approach may even yield a full label encompassing both TB meningitis and pulmonary TB, based on Phase II efficacy data in the former indication and Phase III data in the

latter, should the data be positive. This strategy would accelerate time to approval, while reducing development costs and clinical execution complexity.

Preclinical candidates

- **BV500**, developed through BioVersys's ansamycin discovery platform, is partnered with Shionogi as part of a CHF484m biobuck deal (announced in [July 2025](#)). It is being developed as a potential treatment for broad-spectrum non-tuberculous mycobacteria infections, which include indications such as cystic fibrosis and chronic obstructive pulmonary disease. BioVersys and Shionogi are jointly advancing this programme, with Shionogi bringing expertise in infectious diseases, as well as an established presence in the Japanese market, all while providing BioVersys with non-dilutive funding. Preclinical research will continue throughout 2026, with the next milestone being candidate selection (most likely in 2027).
- **BV200**, developed through the company's TRIC platform, is a combination of anti-virulence agents designed to address *Staphylococcus aureus* infections, for indications such as atopic dermatitis. The programme is in the preclinical stages; an Investigational New Drug filing is targeted for H127. This candidate has Innosuisse grant funding under the Swiss Accelerator programme, providing non-dilutive support for the programme.

Financials

R&D picking up pace in H225

BioVersys reported its FY25 results, representing the first full year of financials following its IPO in February 2025, which raised gross proceeds of CHF76.7m. As a clinical-stage company, BioVersys does not yet generate product revenues; however, it reported CHF0.8m in revenue during the year, which was related to its research collaboration agreement with Shionogi, signed in July 2025 for its preclinical asset BV500, targeting non-tuberculous mycobacteria infections. As a reminder, the agreement includes upfront and near-term payments of up to CHF5.5m (CHF1.5m upfront and up to CHF4m in technology access fees), in addition to potential regulatory and commercial milestone payments of up to CHF479m, contingent on Shionogi exercising its licence option (which we anticipate could occur by 2027, subject to successful development progress). Based on the structure of the agreement, we estimate that the remaining CHF4.7m of the near-term payments will be received and recognised as revenue across FY26 and FY27.

In addition to collaboration revenues, BioVersys reported CHF2.5m in R&D tax credits, grant income and subsidies (FY24: CHF1.2m), reflecting increased development activity. Given that these credits largely reflect reimbursements of eligible R&D expenditures from government programmes, we expect them to fluctuate in line with the company's development activity. Overall, operating income for FY25 increased to CHF3.3m, compared to CHF1.2m in FY24.

Operating expenses for FY25 totalled CHF23.2m (FY24: CHF19.9m), with the increase primarily driven by higher R&D investment. R&D expenses rose 27.5% y-o-y to CHF16.5m (FY24: CHF12.9m), accounting for approximately 71% of total operating costs. As expected, R&D spend was weighted towards the second half of the year (CHF10.3m in H225 vs CHF6.2m in H125), reflecting the ramp-up of preparatory activities for the BV100 registrational Phase III trial. G&A expenses remained broadly stable at CHF6.7m, compared to CHF7.0m in FY24, indicating a relatively controlled corporate overhead base despite increased development activity. Overall, BioVersys reported an operating loss of CHF20.0m in FY25, representing a 6.6% increase from CHF18.7m in FY24. Notably, this was below management's prior guidance of CHF29m. In our view, this variance is likely attributable to the timing of certain R&D expenditures shifting into FY26, rather than any structural change in the underlying cost base.

Estimates revision

FY26 is expected to represent a significant step-up in development activity, driven by the initiation of the BV100 Phase III registrational study (RIV-TARGET), the Phase IIb real world study (RIV-CARE) and the Phase II study for alpbectir in TB meningitis (TBM). Management has guided for an operating loss of CHF40–45m for FY26 and a period end cash balance of c CHF43m, implying a substantial increase in R&D spend as the BV100 programme progresses through its pivotal stage. Reflecting this guidance, we revise our FY26 R&D estimates upwards to CHF37.0m, from CHF21.7m previously, to account for a greater concentration of Phase III-related costs being recognised during the year. We expect the bulk of the BV100 trial-related expenditure to be incurred in FY26, with FY27 increasingly focused on later-stage activities, including data package preparation and regulatory submission.

On the revenue side, we forecast BioVersys to receive CHF2.4m in near-term payments from Shionogi in FY26, alongside CHF2.3m in R&D tax credits and grant income (versus CHF1.6m in our prior estimates), reflecting the higher anticipated level of development activity. Based on the FY25 run-rate and observed cost discipline, we revise our FY26 G&A estimate downwards to CHF8.0m (from CHF9.6m previously). Taken together, we project an operating loss of CHF40.4m for FY26, positioning our estimate at the lower end of management's guided range.

For FY27 we forecast operating income of CHF6.8m (including CHF2.4m from Shionogi) and an operating loss of CHF34.7m, reflecting continued, albeit gradually moderating, development expenditure as key programmes advance towards later-stage milestones.

Funded into 2028

BioVersys ended FY25 with a gross cash balance of CHF82.5m, supported by IPO proceeds and the drawdown of the final CHF7.5m tranche of its European Investment Bank (EIB) loan facility in December 2025. Net cash at year-end stood at CHF60.8m. Based on our updated cash burn projections and factoring in upcoming debt maturities (including the first CHF5m EIB tranche due in August 2027, unless refinanced), we estimate that the company has sufficient funding to support its planned clinical and operational activities into 2028. However, we note that a modest bridging financing requirement (c CHF10–20m) could arise in early 2028, ahead of the anticipated commercial launch of BV100 and the subsequent ramp-up in revenues.

Valuation

We continue to value BioVersys using a risk-adjusted net present value (rNPV) methodology, incorporating its two key clinical-stage programmes, BV100 and alpipectir. Our core assumptions for both programmes remain broadly unchanged following the FY25 results, with one key update relating to BV100.

For BV100, we increase our PoS to 60% (from 50% previously), reflecting the regulatory clearance and initiation of the Phase III registrational trial (with first patient dosing expected in April 2026). We continue to assume a trial cost of around CHF40m, with another c CHF10m attributed to data package preparation, regulatory filing and pre-launch preparations following the Phase III trial. As outlined in our initiation report, we expect the Phase IIb real-world study (RIV-CARE), planned for initiation in Q226, to be largely funded by the Wellcome Trust funds (SGD220m/CHF14m), which we estimate will cover approximately 75% of the study costs.

We maintain our peak sales assumption for BV100 at \$700m in CRAB infections, with a projected market launch in 2028. Following the increase in PoS, our rNPV valuation for BV100 rises to CHF327.9m (CHF56.2/share), up from CHF270.8m (CHF46.4/share) previously, and represents c 80% of our total equity valuation.

For alpipectir, we leave our assumptions unchanged. The self-sponsored TBM study remains on track for initiation in Q226, and we continue to model an initial launch in 2031, with peak sales of \$400m. We apply a PoS of 30% for TBM and 15% for pulmonary TB, resulting in an rNPV of CHF27.6m (CHF4.7/share).

Incorporating the updated PoS for BV100, model roll-forward and the latest net cash position of CHF60.8m, our valuation for BioVersys increases to CHF416.2m (CHF71.3/share), compared to CHF361.6m (CHF61.9/share) previously. Exhibit 3 presents a breakdown of our rNPV valuation for BioVersys.

Exhibit 3: BioVersys risk-adjusted net present value

Product	Indication	Expected launch	Peak sales (\$m)	NPV (CHFm)	Probability	rNPV (CHFm)	rNPV/share (CHF)
BV100	Carbapenem-resistant <i>Acinetobacter baumannii</i>	2028	700	549.7	60%	327.9	56.2
Alpipectir	TB meningitis	2031	100	35.7	30%	10.2	1.7
	Drug-resistant pulmonary TB	2032	300	118.2	15%	17.4	3.0
Net cash at end-December 2025				60.8		60.8	10.4
Valuation				764.4		416.2	71.3

Source: Edison Investment Research

Exhibit 4: Financial summary

	2023	2024	2025	2026e	2027e
Year end 31 December, CHF000s	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS					
Revenue and other income	1,139	1,213	3,268	4,629	6,794
Sales	0	0	800	2,350	2,350
R&D tax credit	858	734	1,342	1,650	3,699
Government and other grants	0	0	0	0	0
Cost of Sales	0	0	0	0	0
Gross Profit	1,139	1,213	3,268	4,629	6,794
R&D expenses	(14,825)	(12,947)	(16,502)	(36,995)	(33,052)
G&A expenses	(4,011)	(6,988)	(6,729)	(8,003)	(8,393)
D&A	(273)	(282)	(297)	(223)	(214)
EBITDA	(17,424)	(18,440)	(19,666)	(40,147)	(34,437)
Operating Profit (before amort. and except.)	(17,697)	(18,722)	(19,963)	(40,369)	(34,651)
Intangible Amortisation	0	0	0	0	0
Exceptionals	0	0	0	0	0
Other	0	0	0	0	0
Operating Profit/(loss)	(17,697)	(18,722)	(19,963)	(40,369)	(34,651)
Net Interest	(604)	3	(1,851)	(259)	(689)
Profit Before Tax (norm)	(18,301)	(18,719)	(21,814)	(40,628)	(35,339)
Profit Before Tax (FRS 3)	(18,301)	(18,719)	(21,814)	(40,628)	(35,339)
Tax	0	0	(16)	0	0
Profit After Tax (norm)	(18,301)	(18,719)	(21,830)	(40,628)	(35,339)
Profit After Tax (FRS 3)	(18,301)	(18,719)	(21,830)	(40,628)	(35,339)
Average Number of Shares Outstanding ('000)	2,986	3,332	5,615	5,615	5,615
EPS - normalised (CHF)	(6.13)	(5.62)	(3.89)	(7.24)	(6.29)
EPS - (IFRS) (CHF)	(6.13)	(5.62)	(3.89)	(7.24)	(6.29)
BALANCE SHEET					
Fixed Assets	581	558	765	542	329
Intangible Assets	0	0	0	0	0
Tangible Assets	581	558	765	542	329
Investments	0	0	0	0	0
Current Assets	33,586	34,398	89,871	51,292	13,457
Cash and cash equivalents	24,376	26,619	82,505	43,190	4,544
Prepaid expenses and other receivables	2,360	1,779	7,366	8,103	8,913
Current financial assets	4,000	6,000	0	0	0
Other	2,850	0	0	0	0
Current Liabilities	9,367	9,673	8,896	14,934	11,216
Trade payables	1,289	706	2,470	2,964	3,557
Accrued expenses	2,203	3,446	2,872	3,446	4,136
Short-term borrowings	1,784	4,305	1,208	6,178	1,178
Other current liabilities	4,091	1,216	2,346	2,346	2,346
Long-Term Liabilities	16,224	14,601	21,929	17,717	18,726
Long-term borrowings	15,678	13,761	21,440	17,228	18,237
Employee benefit liabilities	546	840	489	489	489
Net Assets	8,576	10,682	59,811	19,183	(16,156)
CASH FLOW					
Operating Cash Flow	(11,655)	(15,574)	(21,946)	(39,098)	(33,645)
Net interest	0	0	0	0	0
Tax	0	0	0	0	0
Capex	(49)	(38)	(216)	0	0
Acquisitions/disposals	3,342	(2,000)	6,000	0	0
Equity Financing	(2)	14,331	69,905	0	0
Debt proceeds/repayment	7,132	(251)	2,670	(217)	(5,000)
Dividends	0	0	0	0	0
Others	0	5,113	0	0	0
Net Cash Flow	(1,232)	1,581	56,413	(39,315)	(38,645)
Opening cash	26,561	24,376	26,619	82,505	43,190
Other	(953)	662	(527)	0	0
Closing cash	24,376	26,619	82,505	43,190	4,544
Net cash/(debt)	11,296	9,654	60,776	20,702	(13,951)

Source: Company documents, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by BioVersys and prepared and issued by Edison, in consideration of a fee payable by BioVersys. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.